Lantheus Holdings Inc Stock News

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Lantheus (LNTH) To Contact Him Directly To Discuss Their Options

NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH). The investigation concerns whether Lantheus and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.

Lantheus Holdings, Inc. (NASDAQ:LNTH ) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants Brian A. Markison - CEO & Director Mark Richard Kinarney - Vice President of Investor Relations Paul M.

Lantheus (LNTH) Q2 Revenue Falls 4%

Lantheus remains a highly profitable company with a dominant market share, an exceptionally strong balance sheet with nearly $1 billion in cash, and robust free cash flow. The stock's decline was driven by a slowdown in growth for key products, a surprise business divestiture, a pipeline failure, and a lowered full-year 2025 guidance. Management is actively repositioning the company away from l...

Designed to expand PSMA PET imaging access for patients by increasing batch size by ~50% and enhancing supply resilience PDUFA date set for March 6, 2026

BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), today announced the successful completion of its previously disclosed acquisition of Life Molecular Imaging Ltd. ("Life Molecular"), a subsidiary of Life Healthcare Group Holdings Ltd ("Life Healthcare"). As part of the acquisition, Ludger Dinkelborg, PhD, formerly CEO and Man...

Lantheus remains fundamentally strong despite recent stock drops, with long-term prospects intact for PYLARIFY and Alzheimer's diagnostics. PYLARIFY dominates revenue and has a significant growth runway if adoption expands, representing a multi-billion dollar opportunity by 2030. Alzheimer's market entry is a bullish catalyst, with two promising imaging agents and a large, untapped addressable ...